CIK 0001736730
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Camp4 Therapeutics Corp
Sign in to watch- Ticker
- CAMP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 617-651-8867
- Business address
- 100 TALCOTT AVENUE, SUITE 201, WATERTOWN, MA, 02472
- Open-market buys, last 90 days
- $39,600
- in 1 filing
- Open-market sales, last 90 days
- $2,280,864
- in 3 filings
Net −$2,241,264. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-03 | Mandel-Brehm Josh Chief Executive Officer | Purchase | +6,551 | $1.65 | $11K | 284,968 |
| 2026-04-01 | Mandel-Brehm Josh Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +580,000 | 580,000 | ||
| 2025-12-11 | Mandel-Brehm Josh Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +425,000 | 425,000 | ||
| 2025-09-11 | Mandel-Brehm Josh Chief Executive Officer | Purchase | +6,060 | $1.65 | $10K | 278,417 |
| 2025-04-01 | Mandel-Brehm Josh Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +160,000 | 160,000 | ||
| 2024-10-15 | Mandel-Brehm Josh Chief Executive Officer | Conversion | +605 | 272,357 | ||
| 2024-10-15 | Mandel-Brehm Josh Chief Executive Officer | Conversion · Series B Preferred Stock | −6,791 | 0 |
Page 1 of 1 · 7 trades